Literature DB >> 3789527

Short-course chemotherapy of pulmonary tuberculosis: a new approach to drug dosage in the initial intensive phase.

G Acocella, J H Angel.   

Abstract

An analysis carried out on the dosage schemes adopted in several controlled clinical trials in tuberculosis has indicated that preestablishing the daily doses of isoniazid, rifampicin, and pyrazinamide in the initial intensive phase results in large deviations of the doses administered from those considered appropriate in mg/kg body weight. This is due partly to the variations in the patients' body weight and partly to the restrictions in terms of fine adjustments of dosage imposed by the unitary content of active principle in the available individual preparations of the drugs. The availability of a fixed-triple combination of the same 3 drugs where the content of each component is established multiplying the mg/kg requirement of each drug by 10, allows a complete coincidence between the appropriate and the administered dose simply administering 1 tablet every 10 kg of body weight. The implications of the large overdosing in light patients if the conventional approach is followed are discussed in terms of toxicity and drug purchasing cost, both being of great relevance for Third World countries where the majority of patients are of low body weight.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3789527     DOI: 10.1164/arrd.1986.134.5.1283

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  2 in total

1.  Feasibility of a fixed-dose regimen of pyrazinamide and its impact on systemic drug exposure and liver safety in patients with tuberculosis.

Authors:  Tarjinder Sahota; Oscar Della Pasqua
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

Review 2.  Tuberculosis in the AIDS era.

Authors:  K A Sepkowitz; J Raffalli; L Riley; T E Kiehn; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.